Clinical Trials Browser

Lung Neoplasms

NCT03292133 2025-06-10

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Phase 2 Terminated

11 enrolled 10 charts

Thoracic

Lung Neoplasms

NCT02347839 2024-12-10

NEGOTIATE

Phase 2 Withdrawn

Thoracic

Lung Neoplasms

NCT02025218 2021-04-01

IRENE

Phase 2 Terminated

21 enrolled

Thoracic

Lung Neoplasms

NCT01556191 2021-01-08

LADIE

Phase 2 Completed

379 enrolled

Thoracic

Lung Neoplasms

NCT01405079 2020-02-18

ADJUVANT

Phase 3 Unknown

222 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02745691 2019-12-13

Psychometric Properties of the EORTC QLQ-LC29

Completed

523 enrolled

Thoracic

Lung Neoplasms

NCT02889692 2019-04-11

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Phase 3 Completed

23 enrolled

Thoracic

Lung Neoplasms, Neoplasms

NCT00372515 2018-01-31

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Phase 1 Completed

7 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00310154 2017-05-30

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 1 Completed

45 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00188617 2017-03-14

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Phase 2 Completed

35 enrolled

Thoracic

Lung Neoplasms

NCT01024413 2017-03-01

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Phase 3 Completed

256 enrolled

Thoracic

Lung Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT00062062 2016-12-14

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

65 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00588445 2016-01-22

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Phase 2 Completed

65 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00096486 2016-01-21

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase 1/2 Completed

74 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00062270 2015-10-08

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Phase 1/2 Completed

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02321293 2015-09-02

CURCUMIN

Phase 1 Unknown

20 enrolled

Thoracic

Lung Neoplasms

NCT02518802 2015-08-10

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

Phase 3 Unknown

220 enrolled

Thoracic

Lung Neoplasms

NCT01363557 2014-05-13

ARPEGE

Phase NA Terminated

1 enrolled

CNSThoracic

Brain Neoplasms, Lung Neoplasms

NCT00005806 2013-06-19

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00411047 2013-05-14

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

34 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00068653 2013-04-29

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Phase 2 Completed

27 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00104728 2012-10-31

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

Phase NA Terminated

42 enrolled 3 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00098462 2012-10-04

Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00217698 2012-06-05

Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

63 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00238251 2012-06-05

Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases

Phase 2 Completed

59 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00193336 2011-05-03

Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00238628 2010-07-20

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

Phase 1/2 Completed

12 enrolled

Thoracic

Lung Neoplasms

NCT00144066 2005-09-02

A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Phase 3 Completed

600 enrolled

Thoracic

Lung Neoplasms

Clinical Trials

Therapy for Advanced NSCLC With EGFR 19delins Mutation

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

NEGOTIATE

IRENE

LADIE

ADJUVANT

Psychometric Properties of the EORTC QLQ-LC29

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

CURCUMIN

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

ARPEGE

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases

Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer